Journals / Erciyes Tıp Dergisi / 2012 / Cilt: 34 - Sayı: 4

Uyarılmış pluripotent kök hücrelerin tıpta kullanımı

The use of induced pluripotent stem cells in medicine

Pages
184–187
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this manuscript, the new uses of induced pluripotent stem cells in medicine were discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Induced pluripotent stem cells with self renewal and differentiation abilities were established from mature cells by transcription factors.
📊
Key Findings & Data:These cells may be used in regenerative medicine as embryonic stem cells.
💡
Conclusion & Impact:In this manuscript, the new uses of induced pluripotent stem cells in medicine were discussed.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Induced pluripotent stem cells with self renewal and differentiation abilities were established from mature cells by transcription factors. These cells may be used in regenerative medicine as embryonic stem cells. Recently a mutated gene in a cell obtained from a mouse which had a genetic disease was corrected by gene targeting techniques. These cells were converted into induced pluripotent stem cell by using transcription factor genes and transferred into the same mouse. As a result, the clinical findings of genetic disease mostly disappeared in the mouse. In this manuscript, the new uses of induced pluripotent stem cells in medicine were discussed.

Özet

Kendinin benzerini oluşturma ve tüm hücrelere farklılaşma özellikleri olan indüklenmiş pluripotent kök hücreler, fare olgun hücresinden transkripsiyon faktörleri eklenerek oluşturulur. Bu hücrelerin rejeneratif tıpta embriyonal kök hücre gibi kullanılabilme özelliği vardır. Son olarak yapılan bir çalışmada genetik bir hastalığa sahip fareden alınan hücredeki mutant bir gen, hedef geni düzelten teknoloji kullanılarak düzeltilmiştir. Bu hücre transkripsiyon faktör genleri aktarılarak indüklenmiş pluripotent kök hücre formuna döndürülmüş ve elde edilen hücreler aynı hasta fareye aktarılmıştır. Sonuçta farede genetik hastalığa ait klinik bulguların çoğunlukla düzeldiği görülmüştür. Bu yazıda uyarılmış pluripotent kök hücrelerin tıpta kullanımı konusundaki yeni gelişmeler ele alınmıştır.

🔖

Cite This Article

DİLŞAD, Z. Ç., GÜRAN, Ş. (2022). Uyarılmış pluripotent kök hücrelerin tıpta kullanımı. Erciyes Tıp Dergisi, Cilt: 34 - Sayı: 4, 184–187. https://ajindex.com/articles/502443

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Candolfi M, Kroeger KM, Muhammad AK, Yagiz K, Farrokhi C, Pechnick RN, et al. Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. Curr Gene Ther 2009
  2. 9(5): 409-21. [CrossRef] 2. Guran S. [Proceeded diagnosis and therapy in eye diseases under the light of developments in molecular biology and genetics]. Gulhane Medical Journal 2011
  3. 53(1): 74-6. 3. Nanou A, Azzouz M. Gene therapy for neurodegenerative diseases based on lentiviral vectors. Prog Brain Res 2009
  4. [CrossRef] 4. Plath K, Lowry WE. Progress in understanding reprogramming to the induced pluripotent state. Nat Rev Genet 2011
  5. 12(4): 253-65. [CrossRef] 5. Meir YJ, Weirauch MT, Yang HS, Chung PC, Yu RK, Wu SC. Genome-wide target profiling of piggyBac and Tol2 in HEK 293: pros and cons for gene discovery and gene therapy. BMC Biotechnol 2011
  6. [CrossRef] 6. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006
  7. 126(4): 663-76. [CrossRef] 7. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007
  8. 318(5858): 1917-20. [CrossRef] 8. Zhao XY, Li W, Lv Z, Liu L, Tong M, Hai T, et al. iPS cells produce viable mice through tetraploid complementation. Nature 2009
  9. 461(7260): 86-90. [CrossRef] 9. Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007
  10. 318(5858): 1920-23. [CrossRef] 10. Yoshida Y, Yamanaka S. Recent stem cell advances: induced pluripotent stem cells for disease modeling and stem cell-based regeneration. Circulation 2010
  11. 122(1): 80-7. [CrossRef] 11. Zacharias DG, Nelson TJ, Mueller PS, Hook CC. The science and ethics of induced pluripotency: what will become of embryonic stem cells? Mayo Clin Proc 2011
  12. 86(7): 634-40. [CrossRef] 12. Blum B, Benvenisty N. The tumorigenicity of diploid and aneuploid human pluripotent stem cells. Cell Cycle 2009
  13. 8(23): 3822-30. [CrossRef] 13. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2008
  14. 26(1):101-6. [CrossRef] 14. Denèfle PP. Introduction to gene therapy: a clinical aftermath. Methods Mol Biol 2011
  15. [CrossRef] 15. Wu G, Liu N, Rittelmeyer I,